## Disclosures

### Personal Commercial (10)

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Relationship Category</th>
<th>Compensation Level</th>
<th>Topic Area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>Other - Member national patient selection committee for CLASP studies using PASCAL device to reduce mitral regurgitation</td>
<td>None ($0)</td>
<td>Valvular Heart Disease</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>Research/Research Grants</td>
<td>None ($0)</td>
<td>Valvular Heart Disease</td>
</tr>
<tr>
<td>Evalve/Abbott Structural Heart Disease</td>
<td>Research/Research Grants</td>
<td>None ($0)</td>
<td>Invasive CV Angio and Interventions</td>
</tr>
<tr>
<td>Holistick</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Medtronic</td>
<td>Research/Research Grants</td>
<td>None ($0)</td>
<td>Valvular Heart Disease</td>
</tr>
<tr>
<td>Philips HealthCare</td>
<td>Other - Royalty payments on patented coronary software application</td>
<td>Significant (&gt;= $5,000)</td>
<td>Invasive CV Angio and Interventions</td>
</tr>
<tr>
<td>Philips HealthCare</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Philips HealthCare</td>
<td>Research/Research Grants</td>
<td>None ($0)</td>
<td>Other</td>
</tr>
<tr>
<td>St Jude Medical Corp now Abbott Vascular</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Invasive CV Angio and Interventions</td>
</tr>
<tr>
<td>Tendyne</td>
<td>Data Safety Monitoring Board</td>
<td>Modest (&lt; $5,000)</td>
<td>Valvular Heart Disease</td>
</tr>
</tbody>
</table>

### Personal Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (8)

<table>
<thead>
<tr>
<th>Trial Name</th>
<th>Trial Sponsor</th>
<th>Trial Funding Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>COAPT Trial</td>
<td>Abbott Laboratories</td>
<td></td>
</tr>
<tr>
<td>SUMMIT</td>
<td>Abbott Laboratories</td>
<td></td>
</tr>
<tr>
<td>Triluminate: Triscupid Clipping</td>
<td>Abbott Vascular</td>
<td></td>
</tr>
<tr>
<td>CLASP dMR and fMR</td>
<td>Edwards Life Sciences</td>
<td></td>
</tr>
<tr>
<td>ACTIVE</td>
<td>Edwards Lifesciences</td>
<td></td>
</tr>
<tr>
<td>PARTNER 2</td>
<td>Edwards Lifesciences</td>
<td></td>
</tr>
<tr>
<td>REDUCE trial</td>
<td>Gore</td>
<td></td>
</tr>
<tr>
<td>Low Risk TAVR versus SAVR</td>
<td>MEDTRONIC</td>
<td></td>
</tr>
</tbody>
</table>

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (2)

<table>
<thead>
<tr>
<th>Year</th>
<th>Case Title</th>
<th>Represented</th>
<th>Description</th>
<th>Compensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year</td>
<td>Nature of Claim</td>
<td>Responsible Party</td>
<td>Nature of Event</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------</td>
<td>-------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>Appropriateness of PFO closure</td>
<td>Defendant</td>
<td>Appropriateness of PFO closure following neurological events</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>Outcome after cardiac surgery</td>
<td>Defendant</td>
<td>Death after CABG</td>
<td></td>
</tr>
</tbody>
</table>

† Commercial Funding Source | ‡ Trial Name

**Agreement**

**Certified Education Attestation** | Signed on 9/10/2020  
URL for full agreement: [http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 9/10/2020  
URL for full agreement: [http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

**Embargo** | Signed on 9/10/2020  
URL for full agreement: [http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

**On-Going Obligation Agreement** | Signed on 9/10/2020

---

**ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College’s integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.